antiproliferative

Antiproliferative agent-13 is a compound with antiproliferative activity.

Antiproliferative agent-16 (Antiproliferative agent-16) is an indolyl hydrazide-hydrazone compound with anticancer activity. Antiproliferative agent-16 exhibits specificity toward breast cancer cells (IC50 of 6.94 μM for MCF-7 cells).

Antiproliferative agent-6 (compound 8a) is a potent antitumor compound exhibiting antiproliferative activity. It inhibits cancer cell lines HCT116, MCF-7, H460, and non-tumor aneuploid immortal keratinocyte HaCaT cells with GI50 values of 0.5 μM, 2 μM, 0.7 μM, and 3.5 μM, respectively.

Antiproliferative Agent-27 (Compound 11) is a notable antiproliferative agent that markedly diminishes tumor cell colony formation and induces apoptosis, demonstrating potential for utilization in cancer research [1].

Antiproliferative agent-3 (comp 4) exhibits potent growth inhibitory effects against MCF-7 cells with an IC50 of 0.19 nM [1].

Antiproliferative agent-4 showed good anti-proliferative effects on some cancer cells. antiproliferative agent-4 inhibited tumour growth in nude mice and showed low toxicity. antiproliferative agent-4 reduced the mitochondrial membrane potential of EC109 cells and increased Antiproliferative agent-4 reduced the mitochondrial membrane potential of EC109 cells and increased the apoptosis rate and ROS level.

Antiproliferative Agent-39 (Compound 12) effectively inhibits the proliferation of various cancer cell lines, including A549, SNU-638, Col2, HT1080, and MCF-7, with respective IC50 values of 11, 25, 14, 11, and 6.3 μM [1].

Antiproliferative agent-26 (compound 4g) shows broad-spectrum activity against leukemia, CNS cancers, melanoma, renal, and breast cancers at 10 μM, inhibits colony formation, induces G1 phase cell cycle arrest at 5 μM, and causes S phase cell cycle arrest at 25 μM [1].

Antiproliferative agent-5 (compound 4o) irreversibly and significantly inhibits the proliferation of gastric cancer cells, blocks the cell cycle in the G2 M phase, induces ROS accumulation, and activates cellular autophagy. Antiproliferative agent-5 can be used in anti-cancer research.

Antiproliferative Agent-34 (Compound A14), a multitarget kinase inhibitor, demonstrates IC50 values of 177 nM for EGFR L858R/T790M and 1567 nM for EGFR WT. Additionally, it inhibits JAK2, ROS1, FLT3, FLT4, and PDGFRα with respective IC50s of 30.93 nM, 106.90 nM, 108.00 nM, 226.60 nM, and 42.53 nM. In normoxic conditions, it suppresses the proliferation of H1975 and HCC827 cells with IC50 values below 40 nM, while under hypoxic conditions, its potency increases 4-6 fold, yielding IC50 values less than 10 nM [1].

Antiproliferative Agent-42 (Compound 7m), a dihydrodipyrrolo compound, exhibits antiproliferative activity against the Panc-1 cell line, with an IC 50 of 12.54 μM [1].

Antiproliferative agent-36 is a broad-spectrum anticancer benzothiazolylhydrazone-derived compound that inhibits cell proliferation.

Antiproliferative agent-32 (Compound 1c) impedes phosphorylation in the PI3K Akt mTOR signaling pathway, restricts proliferation of Huh7 and SK-Hep-1 cells, induces apoptosis, and causes mitochondrial damage, making it a potential candidate for hepatocellular carcinoma research [1].

Antiproliferative agent-30 (Compound 8g) exhibits broad-spectrum antiproliferative activity, with IC50 values of 0.054 nM, 0.008 nM, and 0.144 nM against HCT-116, K562, and MV-4-11 cancer cell lines, respectively. It inhibits tubulin assembly, FLT3, and Abl1 kinases and shows vascular-disrupting capabilities. Additionally, it displays an anticancer effect against acute myeloid leukemia (AML) with FLT3-ITD-TKD mutations [1].

Antiproliferative Agent-19, an anti-cancer compound, demonstrates antiproliferative effects by inducing apoptosis in lung cancer cells and causing cell cycle arrest in the G2/M phase.

Compound 5k (Antiproliferative Agent-18) is an antiproliferative agent that exhibits moderate antibacterial and antifungal activities [1].

Antiproliferative agent-7 (compound 8f) is a potent anti-proliferative agent that promotes ROS production and induces apoptosis.

Antiproliferative Agent-11, a selective Ruthenium(II)-Tris-pyrazolylmethane complex, exhibits antiproliferative effects on MCF-7, HeLa, 518A2, HCT116, and RD cancer cell lines with IC50 values of 6, 10, 6.8, 6.7, and 6 μM, respectively. This compound is utilized in cancer research.

Antiproliferative Agent-20 is a potent, orally active anticancer compound exhibiting both antiproliferative and anti-angiogenic activities.

Antiproliferative Agent-38 (COM 18), a tetracyclic compound, features a reactive ring nitrogen (likely the quinoline moiety) that resists N-alkylation. Despite its classification, it neither exhibits anti-malarial properties nor inhibits cancer cell proliferation [1].

Antiproliferative agent-37 (compound 10J) inhibits cell proliferation by arresting cells at the G2 M phase of the cell cycle [1].

Antiproliferative Agent-25 (Compound 3s4) is a selective PRMT5 inhibitor displaying an IC50 of 0.11 μM. It elevates hnRNP E1 protein levels and forms hydrogen bond interactions with SAM and the E444 residue of PRMT5. This compound exhibits antiproliferative effects in A549 cells by inducing apoptosis and inhibiting migration, albeit it presents high clearance rates, with half-lives of 21.8 minutes in human liver microsomes and 4.7 minutes in rat liver microsomes [1].

Antiproliferative agent-15 is a reagent with anticancer activity. Antiproliferative agent-15 showed antiproliferative activity against human colon cancer (HCT116 and HCT15) and brain cancer (LN-229 and GBM-10).

Antiproliferative Agent-10, a ruthenium(II)-tris-pyrazolylmethane complex, functions as an anti-tumor compound by impeding cancer cell growth through the inhibition of mitochondrial calcium uptake.

Antiproliferative Agent-17 exhibits both antimicrobial properties against Gram-positive bacteria and anticancer activity [1].

Antiproliferative agent-23, a microtubule-destabilizing agent (MDA), disrupts the tubulin-microtubule system, leading to apoptosis through a mitochondrion-dependent pathway. This involves downregulation of Bcl-2 protein, upregulation of Bax and Cyt c proteins, and activation of the caspase cascade. Additionally, it induces reactive oxygen species (ROS)-mediated endoplasmic reticulum stress in A549/CDDP cells (cisplatin-resistant cancer cell line) through the PERK/ATF4/CHOP signaling pathway, demonstrating anti-tumor activity [1].

Antiproliferative Agent-10 (Compound 1), a ruthenium(II)-tris-pyrazolylmethane complex, functions as an anti-tumor agent by impeding cancer cell proliferation through the inhibition of mitochondrial calcium uptake [1].

Antiproliferative agent-8 (Compound 5a) is an anti-cancer compound that significantly increases P53 levels.

Antiproliferative Agent-41 (Compound 14), classified as indanorine [1], functions as an antiproliferative compound.

Antiproliferative agent-40 (Compound 9) effectively inhibits the proliferation of HT1080 and MCF-7 cancer cells, with IC50 values of 52 μM and 8.2 μM, respectively [1].

Antiproliferative Agent-33 (Compound 2g) serves as an anti-proliferative, antifungal, and antibacterial agent, effectively inhibiting the proliferation of MDA-MB-231 cells (IC50: 16.38 μM), impairing the growth of gram-negative bacteria, and restraining S. faecalis with an MIC of 8 μg/mL [1].

MT189 (Antiproliferative agent-14) is a potent tubulin polymerization inhibitor, with an IC50 of 3.41 μM. Antiproliferative agent-14 has excellent antiproliferative activity. Antiproliferative agent-14 possess the ability to arrest cells at G2/M phases of the cell cycle.

VTP50469 is a highly selective and orally active inhibitor of Menin-MLL interaction( Ki: 104 pM) and has potently anti-leukemia activity.

BI-2865 is a non-covalent pan-KRAS inhibitor.BI-2865 binds to KRAS WT, G12C, G12D, G12V, and G13D mutants with KD values of 6.9, 4.5, 32, 26, and 4.3 nM, respectively.BI-2865 showed antiproliferative activity in BaF3 cells expressing KRAS G12C, G12D, or G12V mutants. BI-2865 showed antiproliferative activity on BaF3 cells expressing KRAS G12C, G12D or G12V mutants with an average IC50 value of approximately 140 nM.

Pasireotide Acetate is a stable cyclohexapeptide somatostatin mimic

Telaglenastat (CB 839) (IC50 of 24 nM), an effective, specific, and oral inhibitor, which is bioavailable glutaminase, for recombinant human GAC.

Cyclic-di-GMP disodium (5GP-5GP disodium) is a bacterial second messenger and a STING agonist involved in a variety of prokaryotic processes including biofilm formation, motility, and cell cycle progression.Cyclic-di-GMP disodium displays antiproliferative activity against cancer cells, inducing elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP disodium can be used in cancer research cancer.

Dipyrithione appears to have novel cytotoxicity and potent broad-spectrum antitumor activity

Emodin (Frangula emodin) is a naturally occurring anthraquinone present in the roots and barks of numerous plants; exerts antiproliferative effects in Y cells that are regulated by different signaling pathways.

Geniposide is an iridoid glycoside with a variety of biological activities including neuroprotective, anti-diabetic, antiproliferative, and antioxidative activity. Geniposide has been shown to regulate Nrf2 translocation.

5-fluorouridine is also known as FUrd, 5-Fluorouracil 1-beta-D-ribofuranoside, 5-Fur, or 5-Fluoro-uridine. 5-fluorouridine is a solid. This compound belongs to the pyrimidine nucleosides and analogues. These are compounds comprising a pyrimidine base attached to a sugar. 5-fluorouridine is known to target uridine phosphorylase. FUrd is often used in chemical and biochemical comparison studies with fluorouracil and thymine analogs.

18β-Glycyrrhetinic acid (Enoxolone) is the major bioactive component of Glycyrrhizae Radix and possesses anti-ulcerative, anti-inflammatory and antiproliferative properties.

Tetraethylammonium chloride is a quaternary ammonium compound. It is a non-selective potassium channel blocker. It is a good substrate for organic cation transporter proteins and has antitumor properties.

Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib monohydrate binds to and inhibits the growth-promoting activities of these kinases. Apparently, because of its less stringent binding affinity for the BCR-ABL kinase, Dasatinib monohydrate has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations.

Dienogest (STS 557) is an orally-active, semisynthetic, fourth generation, nonethinylated progestogen with antiproliferative, antiandrogenic, anti-inflammatory and antiangiogenic activities that is used in hormone therapy and as a female contraceptive.

Rutin (Quercetin 3-O-rutinoside), a flavonoid, has a variety of biological activities including antiallergic, anti-inflammatory, antiproliferative, and anticarcinogenic properties.

Ethyl ferulate (Ethyl 4'-hydroxy-3'-methoxycinnamate) is the alkyl ester derivative of ferulic acid which is a naturally occurring plant product with anti-oxidative, anti-inflammatory, neuroprotective, and antiproliferative activities.

2,3,5-Trimethylphenol (Isopseudocumenol) is a antiproliferative agent, pGI50= 0.36 to T. pyriformis.